دورية أكاديمية
أعرض في EDS

Expression and clinical implications of HLA-G and PD-L1 following kidney transplantation: A cohort study.

التفاصيل البيبلوغرافية
العنوان: Expression and clinical implications of HLA-G and PD-L1 following kidney transplantation: A cohort study.
المؤلفون: Botelho SM; Stricto Sensu Graduate Program in Health Sciences, School of Medicine, Federal University of Goiás (UFG), Goiânia, Brazil., Wastowski IJ; State University of Goiás (UEG), Goiânia, Brazil., Simões RT; Stricto Sensu Graduate Program, Faculdade Santa Casa de Belo Horizonte (FSCBH), Belo Horizonte, Brazil., Cysneiros MAPC; Stricto Sensu Graduate Program in Health Sciences, School of Medicine, Federal University of Goiás (UFG), Goiânia, Brazil., da Silva Menezes A Jr; Faculty of Medicine of the Federal University of Goiás (UFG), Goiânia, Brazil., Rezende AL; Faculty of Medicine of the Federal University of Goiás (UFG), Goiânia, Brazil., da Silva NA; Stricto Sensu Graduate Program in Health Sciences, School of Medicine, Federal University of Goiás (UFG), Goiânia, Brazil.
المصدر: Medicine [Medicine (Baltimore)] 2023 Nov 17; Vol. 102 (46), pp. e36053.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Kidney Transplantation*/adverse effects, Humans ; HLA-G Antigens ; B7-H1 Antigen ; Cohort Studies ; Graft Rejection
مستخلص: Kidney transplantation (KT) is the preferred treatment for end-stage renal diseases. Human leukocyte antigen G (HLA-G) and programmed death-ligand 1 (PD-L1) have notable clinical and therapeutic significance in transplantation because of their roles in promoting tolerance. This study aimed to assess HLA-G and PD-L1 levels at various stages following KT. A cohort of 12 patients was monitored from the pretransplant phase to 12 months post-surgery. Blood samples were taken at specific intervals: before kidney transplantation (T0), and then on the 7th (T7), 30th (T30), 90th (T90), 180th (T180), and 365th days post transplantation. Renal biopsies were performed in patients with graft dysfunction. Plasma levels of soluble HLA-G (sHLA-G) and PD-L1 were quantified using enzyme-linked immunosorbent assays. Additionally, immunohistochemistry was used to detect the presence of both molecules in biopsy samples. Multivariate analysis indicated that episodes of rejection were correlated with decreased expression of sHLA-G (P < .001) and PD-L1 (P < .001). Over the course of the study, the sHLA-G levels also declined (P < .001). Patients who had been transfused had lower PD-L1 levels (P = .03). Furthermore, kidney recipients from related live donors had increased HLA-G expression (P < .001). Our findings suggest that diminished HLA-G and PD-L1 levels correlate with an increased risk of graft rejection. Notably, HLA-G expression significantly decrease after the third-month posttransplantation.
Competing Interests: The authors have no conflicts of interest to disclose.
(Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: Gouveia DSES, Bignelli AT, Hokazono SR, et al. Analysis of economic impact between the modality of renal replacement therapy. J Bras Nefrol Nefrol. 2017;39:162171.
Auchincloss H, Sultan H. Antigen processing and presentation in transplantation. Curr Opin Immunol. 1996;8:681–7.
Rebmann V, Bartsch D, Wunsch A, et al. Soluble total human leukocyte antigen class I and human leukocyte antigen-G molecules in kidney and kidney/pancreas transplantation. Hum Immunol. 2009;70:995–9.
Boegel S, Löwer M, Bukur T, et al. HLA and proteasome expression body map. BMC Med Genomics. 2018;11:1–12.
Zhang Y, Yu S, Han Y, et al. Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment (Review). Oncol Lett. 2018;15:699–709.
Lin A, Yan WH. Heterogeneity of HLA-G expression in cancers: facing the challenges. Front Immunol. 2018;9:2164.
Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765–72.
Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887–95. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1396582 .
Nishimura H, Minato N, Nakano T, et al. Immunological studies on PD-1-deficient mice: Implication of PD-1 as a negative regulator for B cell responses. Int Immunol. 1998;10:1563–72.
Vibhakar R, Juan G, Traganos F, et al. Activation-induced expression of human programmed death-1 gene in T- lymphocytes. Exp Cell Res. 1997;232:25–8.
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the Pd-1 immunoinhibitory receptor by a Novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11015443 .
Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203:883–95.
Gao W, Demirci G, Strom TB, et al. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation. 2003;76:994–9.
Yang J, Riella LV, Chock S, et al. The Novel costimulatory programmed death ligand 1/B71 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol. 2011;187:1113–9.
Rebmann V, LeMaoult J, Rouas-Freiss N, et al. Report of the wet workshop for quantification of soluble HLA-G in Esse, 2004. Hum Immunol. 2005;66:853–63.
Gonçalves A, Oliveira J, Oliveira C, et al. Relevance of HLA-G, HLA-E and IL-10 expression in lip carcinogenesis. Hum Immunol. 2016;77:785–90.
Hollander M, Wolfe DA. Nonparametric statistical methods. 2nd ed. New York, N.Y.: John Wiley & Sons.
Mccullagh P, Nelder JA. Generalized linear models. CRC Press. 1989.
Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika;73:13–22.
Piancatelli D, Maccarone D, Colanardi A, et al. Evaluation of plasma levels of soluble HLA-G and HLA-G genotypes in kidney transplant recipients. Transplant Proc. 2020;52:1559–61. Available at: https://doi.org/10.1016/j.transproceed.2020.02.044.
Clark B, Unsworth DJ. HLA and kidney transplantation. J Clin Pathol. 2010;63:21–5.
Frohn C, Fricke L, Puchta JC, et al. The effect of HLA-C matching on acute renal transplant rejection. Nephrol Dial Transplant. 2001;16:355–60.
Crispim JCO, Duarte RA, Soares CP, et al. Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transpl Immunol. 2008;18:361–7.
Jin HL, Li CR, Xiao L, et al. Clinical relevance of sHLA-G-mediated with better graft acceptance in early posttransplantation. Transplant Proc. 2012;44:1259–61.
Xiao L, Shi B, Gao Y, et al. Applications of monitoring human leukocyte antigen g and its inhibitory receptors in post-renal transplantation. Zhonghua Yi Xue Za Zhi. 2010;90:2524–7.
Krongvorakul J, Kantachuvesiri S, Ingsathit A, et al. Association of soluble human leukocyte antigen-G with acute tubular necrosis in kidney transplant recipients. Asian Pac J Allergy Immunol. 2015;33:117–22.
Poláková K, Bandžuchová H, Žilinská Z, et al. Analysis of HLA-G expression in serum and biopsy samples of kidney transplant recipients. Immunobiology. 2015;220:533–7.
Okushi Y, Okino K, Mukai K, et al. Circulating and renal expression of HLA-G prevented chronic renal allograft dysfunction in Japanese recipients. Clin Exp Nephrol. 2017;21:932–40.
المشرفين على المادة: 0 (HLA-G Antigens)
0 (CD274 protein, human)
0 (B7-H1 Antigen)
تواريخ الأحداث: Date Created: 20231121 Date Completed: 20231127 Latest Revision: 20231129
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC10659681
DOI: 10.1097/MD.0000000000036053
PMID: 37986370
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000036053